Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Discovery and Validation of Proteogenomic Biomarker Panels in Liver Transplant Recipients

Study:

Discovery and Validation of Proteogenomic Biomarker Panels in a Prospective Serial Blood & Urine Monitoring Study of Liver Transplant Recipients

Rationale:

n/a

Purpose:

The main focus of this study is to develop blood and/or urine tests that will help to detect early signs of rejection in people who have had a liver transplant. Researchers will examine blood, urine, and tissue samples and try to identify markers for certain conditions such as rejection, response to therapy, and scarring of the liver. Additionally, researchers would like to identify biomarkers that can detect damage to the native kidneys before blood levels of creatinine rises. By studying gene expression, researchers hope to be able to diagnose these conditions earlier and improve liver survival.

Study Status: Recruiting

Recruiting:
n/a

Condition Intervention Phase
Proteogenomic Monitoring in Liver Transplant Recipients n/a N/A

Verified by National Institute of Allergy and Infectious Diseases (NIAID) July, 2013

Sponsored by: National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by: National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov identifier: NCT01672164

Study Type: Interventional

Study Design: Observational Model: Cohort, Time Perspective: Prospective

Cleveland Clinic Foundation
Cleveland, Ohio 44295
United States

Josh Levitsky, MD, MS., Study Chair
MICHAEL ABECASSIS, MD, MBA., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site